Global Breast Cancer Drug Market Offers US$ 40 Billion Market Opportunity Across Multiple Drug Classes Like Vaccines, Antibodies, Small Molecule, Peptides & Radiopharmaceuticals – ResearchAndMarkets.com
January 16, 2020DUBLIN–(BUSINESS WIRE)–The “Global Breast Cancer Drug Market & Clinical Trial Insight 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.
Global Breast Cancer Drug Market & Clinical Trial Insight 2025 Report Highlights:
- Global Breast Cancer Drug Market: US$ 40 Billion Opportunity
- Global Breast Cancer Drug Clinical Pipeline: More Than 550 Drugs
- Marketed Breast Cancer Drugs: More Than 90 Drugs
- Comprehensive Clinical Insight & Patent Information
- Drug Trials, Pricing, Dosage, Cancer Prevalence Insight: 130 Graphs/Charts
The applied science research has marked tremendous advancements in cutting off the epidemic cancer scenarios all around the world but every year unexpectedly more than one million new cases of breast cancer are reported. Breast cancer is somehow responsible for accounting about 10% of all the cancer cases worldwide. Although there has been a limitation in the treatment facilities for cancer cases but since few years there has been an excellent increase in the awareness level with regarding its impact on the survival rates in the case of early diagnosis of breast cancer.
Global Breast Cancer Drug Market Offers US$ 40 Billion Market Opportunity Across Multiple Drug Classes Like Vaccines, Antibodies, Small Molecule, Peptides, Radiopharmaceuticals etc.
The increasing cases of breast cancer have however opened a very prominent and novel opportunity for the market of breast cancer all over the world. Several therapies and products gets marketed under the category of breast cancer treatment market and some of these products or therapies include: chemotherapies, targeted therapies, hormonal therapies and many more. The unmet needs with respect to unconvincing safety data and severe adverse effects are however enhancing the realistic opportunities for the expansion of breast cancer drug market focused on improved efficacy and safety. The factors such as improved safety and efficacy are demanding the primary research focus from the R&D groups of the pharmaceutical companies.
The pharmaceutical R&D groups are compelled to effectively unravel and understand the key dynamics of the market, competitive market, pipeline of the drug and the market forecast to better provide a realistic perspective of the market of breast cancer
The participation of several major key players majorly towards the research and development of novel drugs is expected to develop the market of breast cancer drugs lucratively in the coming years. On average, the engagement of the extensive research groups in developing the drugs for breast cancer calls for an unpredictable table of opportunities for them as well as the patients. The inevitable advancements with respect to customization and designing and the strong pipeline of the therapeutic agents are proving to be an effective treatment option than the already existing therapies.
High awareness, well-established healthcare infrastructure are some of the factors that are however responsible for covering a large market share and owing to this, North America since few years is capable of holding the largest market share of global breast cancer drug market. Growing research and development investments and increasing incidence of breast cancer is adding to the conclusion that Europe is among the second largest market share of the global breast cancer drug market. Countries of Asia-Pacific are expected to be among the new additions for the breast cancer drug market in the next few years.
According to research report findings, the global breast cancer drug market is expected to rise up to many folds.
Report gives in depths insight on multiple perspectives of the breast cancer drug market and ongoing clinical trials. Each section of the report offers a deep insight view about the current market data, market drivers, trends and opportunities, drugs that are top-selling, major key players and the competitive outlook related to the market.
Key Topics Covered:
1. Introduction to Breast Cancer Drug Market
1.1 Overview
1.2 Historical Development of Breast Cancer Drugs
2. Global Breast Cancer Prevalence & Statistics
2.1 North America
2.2 Europe
2.3 Asia-Pacific
3. Available Therapeutics for Breast Cancer Management
3.1 Hormonal Therapy
3.2 CDK 4/6 Inhibitors
3.3 HER2 Inhibitors
3.4 PI3K & mTOR Inhibitors
3.5 PARP Inhibitors
3.6 Other Therapeutics
4. Breast Cancer Therapeutics Clinical Insight
4.1 Overview
4.2 Breast Cancer’s Clinical Trials by Drug Class & Phase
5. Global Breast Cancer Drug Clinical Pipeline Insight
5.1 By Phase
5.2 By Country/Region
5.3 By Biomarker
5.4 By Formulation
5.5 By Company
5.6 By Mechanism
6. Global Breast Cancer Drug Clinical Trial Insight: Unknown
6.1 Overview
6.2 Clinical Pipeline Insight
7. Global Breast Cancer Drug Clinical Trial Insight: Research Phase
7.1 Overview
7.2 Clinical Pipeline Insight
8. Global Breast Cancer Drug Clinical Trial Insight: Preclinical Phase
8.1 Overview
8.2 Clinical Pipeline Insight
9. Global Breast Cancer Drug Clinical Trial Insight: Clinical Phase
9.1 Overview
9.2 Clinical Pipeline Insight
10. Global Breast Cancer Drug Clinical Trial Insight: Phase-I
10.1 Overview
10.2 Clinical Pipeline Insight
11. Global Breast Cancer Drug Clinical Trial Insight: Phase-I/II
11.1 Overview
11.2 Clinical Pipeline Insight
12. Global Breast Cancer Drug Clinical Trial Insight: Phase-II
12.1 Overview
12.2 Clinical Pipeline Insight
13. Global Breast Cancer Drug Clinical Trial Insight: Phase-II/III
13.1 Overview
13.2 Clinical Pipeline Insight
14. Global Breast Cancer Drug Clinical Trial Insight: Phase-III
14.1 Overview
14.2 Clinical Pipeline Insight
15. Global Breast Cancer Drug Clinical Trial Insight: Preregistration
15.1 Overview
15.2 Clinical Pipeline Insight
16. Global Breast Cancer Drug Clinical Trial Insight: Registered
16.1 Overview
16.2 Clinical Pipeline Insight
17. Marketed Breast Cancer Drug Clinical Insight by Company
18. Competitive Landscape
18.1 Novartis
18.2 Amgen
18.3 Eli Lilly
18.4 Merck
18.5 Pfizer
18.6 GlaxoSmithKline
18.7 Roche
18.8 Takeda Pharmaceuticals
18.9 Teva Pharmaceuticals
18.10 AstraZeneca
18.11 G1 Therapeutics
18.12 Nerviano Medical Science
18.13 Genentech
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/u0ckh0
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900